Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 6,735 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CHANGE Study Clear all
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Completed No phase listed Observational

A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees

NCT03125499
View directory record Official record
Conditions
Mild to Moderate Knee OA
Interventions
Previous treated with TPX-100
Other
Lead sponsor
OrthoTrophix, Inc
Industry
Eligibility
25 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Covina, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 27, 2026, 11:53 AM EDT
Not listed Phase 1 Interventional

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

NCT04450732
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
Interventions
GQ1001
Drug
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 27, 2026, 11:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe

NCT04565821
View directory record Official record
Conditions
Inflammatory Disease, Permeability; Increased, Crohn Disease, Inflammatory Bowel Diseases, Environmental Enteropathy
Interventions
IPD Probe via TNIT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Active, not recruiting Not applicable Interventional

The Inspiring Action to Prevent Diabetes Intervention

NCT06001801
View directory record Official record
Conditions
PreDiabetes
Interventions
Diabetes Prevention Program, INSPIRA
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women

NCT03270111
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Supervised Exercise, Home-based Exercise, Reduced Energy Diet, Group Phone Calls
Behavioral
Lead sponsor
Carol Fabian, MD
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional

Teach-back Method on Patient Satisfaction and Adherence to Wound Care Regimen

NCT04377971
View directory record Official record
Conditions
Keratinocyte Carcinoma
Interventions
SOC education, Ask-tell-ask education, Participant satisfaction survey, Wound care adherence survey
Behavioral · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 27, 2026, 11:53 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABBV-291
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

NCT01290471
View directory record Official record
Conditions
Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
Interventions
U3-1565
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional

Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study

NCT02914964
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Swank Diet, Wahls Elimination Diet
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional Results available

Study to Compare Marginal Bone Loss Around Implants From Two Dental Implant Systems.

NCT00746187
View directory record Official record
Conditions
Jaw, Edentulous, Partially
Interventions
ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm., 3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm
Device
Lead sponsor
Dentsply Sirona Implants and Consumables
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 27, 2026, 11:53 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Timed Aspirin Chronobiome Study

NCT03590821
View directory record Official record
Conditions
Healthy
Interventions
Aspirin 81 mg, Celecoxib 200mg capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Aging Resources to Thrive (HART)

NCT03739762
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
i-STAND, Healthy Living control
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
60 Years to 89 Years
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 27, 2026, 11:53 AM EDT
Recruiting Phase 1 Interventional

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT06896188
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Retifanlimab, Chemotherapy, 9-ING-41
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional

Functional Prehabilitation and Major Elective Surgery

NCT01943773
View directory record Official record
Conditions
Surgical Complication, Physical Therapy, Timed Up and Go
Interventions
Functional Assessment, Prehabilitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness Training for Smoking Cessation

NCT05440903
View directory record Official record
Conditions
Smoking Cessation
Interventions
Headspace, TEDTalk
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

NCT05166096
View directory record Official record
Conditions
Healthy
Interventions
Rho-11, aspirin 325mg
Drug
Lead sponsor
Rhoshan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Safer Drinking Spaces Study

NCT07527988
View directory record Official record
Conditions
Sexual Violence, Bystander Intervention
Interventions
Safe Bars active bystander training
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
3,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 27, 2026, 11:53 AM EDT
Active, not recruiting Phase 1 Interventional

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03907527
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC V8, Stage III Ovarian Cancer AJCC V8, Stage III Primary Peritoneal Cancer AJCC V8, Stage IIIA Fallopian Tube Cancer AJCC V8, Stage IIIA Ovarian Cancer AJCC V8, Stage IIIA Primary Peritoneal Cancer AJCC V8, Stage IIIA1 Fallopian Tube Cancer AJCC V8, Stage IIIA1 Ovarian Cancer AJCC V8, Stage IIIA2 Fallopian Tube Cancer AJCC V8, Stage IIIA2 Ovarian Cancer AJCC V8, Stage IIIB Fallopian Tube Cancer AJCC V8, Stage IIIB Ovarian Cancer AJCC V8, Stage IIIB Primary Peritoneal Cancer AJCC V8, Stage IIIC Fallopian Tube Cancer AJCC V8, Stage IIIC Ovarian Cancer AJCC V8, Stage IIIC Primary Peritoneal Cancer AJCC V8, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8
Interventions
PRGN-3005 UltraCAR-T cells
Biological
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 27, 2026, 11:53 AM EDT
Completed No phase listed Observational

Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis

NCT01343524
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
4 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Phase 2 Interventional

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT00114920
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Not applicable Interventional Results available

Fostering MAT Use in Justice Populations

NCT04363320
View directory record Official record
Conditions
Opioid-use Disorder, Recidivism
Interventions
NIATx Coaching, ECHO
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 27, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Results available

Effects of Sildenafil on CFTR-dependent Ion Transport Activity

NCT01132482
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 27, 2026, 11:53 AM EDT